View printer-friendly version
Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors
THOUSAND OAKS, Calif., July 9 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) announced today that its Board of Directors has appointed Rebecca M.
Henderson, Ph.D., to the Company's Board. Dr. Henderson, 48, has recently
joined the faculty at the Harvard Business School, having been the Eastman
Kodak LFM Professor of Management at the Massachusetts Institute of Technology
(MIT) Sloan School since 1999. She specializes in technology strategy and the
broader strategic problems faced by firms in high technology industries. From
1995 to 1999, Dr. Henderson was a tenured associate professor at the MIT Sloan
School. She has been a director of IDEXX Laboratories, Inc. since 2003. Dr.
Henderson's appointment brings the number of Amgen Board members to 13. Dr.
Henderson will serve as a member of the Corporate Responsibility and
Compliance and Governance and Nominating Committees of the Board.
Dr. Henderson has also been a research associate at the National Bureau of
Economic Research since 1995. She also sits on the editorial boards of
Management Science, Research Policy and Organization Science.
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe and effective
medicines from lab, to manufacturing plant, to patient. Amgen therapeutics
have changed the practice of medicine, helping millions of people around the
world in the fight against cancer, kidney disease, rheumatoid arthritis, and
other serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-6979 (media)
Arvind Sood, 805-447-1060 (investors)